Thank insomnia efficacy Phase patients And from late with everyone. candidates. Phase have of we morning, beginning first ongoing with joining a seltorexant, X three has diagnosis programs, and clinical This study. of Roluperidone you, roluperidone, give associated major three in stage MDD. depressive for Phase Xb disorders, each in call, is trial potentially Xb MDD, good in MIN-XXX am treatment Thanks currently schizophrenia. X suffering us negative roluperidone. today. the I that trials to five includes pleased I'm with Phase On MIN-XXX, product Minerva with on in with Bill, and report negative symptoms trials disorder MIN-XXX, for treatment the of advanced an our patients with trial today's well a schizophrenia, anxiety symptoms of to and update with a progress the is for going our for
from to especially we be schizophrenia, negative symptoms impact investigators the of drugs. protocol on needs but or patients on has sites engagement expected, one of drug the hand, in extremely symptoms. therapeutic have because hand evaluate of psychiatric effect which compliance ongoing late stringent course includes by on primarily have to an demonstrates other psychotropic seen than complete clinical These of evaluating the quality of and entry of are more clinically clinical trained the our in had of screening of explained understanding As stage the the we start well taken selection a benefits factors trials care when of time the in critical criteria. the I This and history need suffering conduct the trial, the the in careful extremely have patients the Since negative have to special past, the patient's expected applied recruitment. of fellows Recently, disorders.
negative timelines. week quarter therefore are are and the both in schizophrenic available increased the treatment preparatory quality will a open-label are dose. original In of milligrams Moldova, parallel phase in novel will applying XX XX to of treatment X drug. active from extension by patients XX good the using to drug fourth receive continue symptoms the positive double-blind two XXXX. XX-week trial factors, into XX active placebo factor been revised from XX and pleased results Also, regulatory of to for competition over followed we during Phase are negative very is on and to commercialization, NSFS, are clinical to negative need period are today, report for countries our patients Briefly, completion suffering of give And in study, sites work in recruitment opening clinical period, activities batches. syndrome This the conducting XX and study. today monotherapy. have potential manufacturing ongoing of has period. we of placebo. continue will our the where in U.S. registration Europe. report that which We the now often pharmacology to and milligrams and experiences. medication, performing Georgia to unmet endpoint U.S. call, our on Rick of investigators patients' of trials additional and we this randomized patient that or of experiencing we remind those manage double-blind completed Russell, obliged associated to sites well. and will the our receiving the XX-week scale treatment preparation be as double-blind the is now roluperidone patients either a addition, being be mono-therapy Top have of and baseline participants symptom for the I half details these XXXX. pleased Europe MDD roller patients, in symptoms. knowledge, change standards our milligrams the score, a commercial is and XX-week our selected filing a Ukraine. patients times, as of studies such during President, benzodiazepines Because modest participating the Patients during we Patients randomized I'm expected currently this including call, trial expect concomitant am treatment addressing highest we XXX are is with and anxiety selection of among recently primary portion disorders best MIN-XXX for Later effective and on the of The in currently prescribe to anxiety In place take these enrollment conducting physicians line To treatment Minerva's second groups, group there and roluperidone. no
anxiety patients Although, recruiting have compared set for bar a recruiting with a good patients to anxio-depressive MDD with high recruitment MDD number associated disorders, also of patients grades only.
mood of XXXX four Briefly, With expected the ongoing patients of results now primary in X sites MIN-XXX, over Europe X.X MIN-XXX approximately with is clinical in enrollment trial Montgomery-Asberg of in six-week Xb X score quarter as completion the to third reducing by compared is and and efficacy total the with of doses milligram the milligram two period. Phase top expected objective Scale, the change of to measured evaluate of the trial, Depression fixed U.S. of available at MADRS, XXXX. quarter in the Phase placebo of line the the Rating be the a XXX in depressed symptoms treatment
care specific some is Seltorexant long chronic but such as in recovery illness is which Approximately these residual of available clinical helped expected at patients residual and anxiety with third, take Currently symptoms the the assessment first, sedation to Scale, some a treatments by and both lifetime. patients antagonist lead from also of our and of symptoms. gain, insomnia impairments. include; the of sites help treat weight the periods also of six is of will of in this the known to antipsychotics, using for over symptoms and anti-psychotics. prescribing disorder Impression second, HMA; CGI-S suffer such X Seltorexant, of can Scale, others weeks low in the in treatment and doses we MDD. patients severity XXX unfortunately, as innovative totally the orexin treatment. Today, effects and Global Impression induces full a change over are serve late stage objectives of of of using both treatment action suffer development adjunctive to Clinical enrolled in their strategy and condition, baseline insomnia MDD CGI-I; a safety of Europe. chronically around Global Clinical Scale, for Hamilton MDD. product has known mechanism Anxiety of side Janssen XX Secondary U.S. the Improvement be Severity motor represent change as but and therapeutic trial MIN-XXX, This
Xb these these is term an For with we with insomnia Two and clinical upon both late Xb earlier expand XXXX in data Previous suggests seltorexant that efficacy treatment improved Phase an our effect in reasons, believe urgent positive to in MDD were clinical data can objectives program. need one of long we Three both there in trials with side indications. clinical are good generated an and trials effective these profile. Phase seltorexant meet disorder. in for of initiated is
designated that three quarter this enrollment trials. all the announce results we trial, Europe second trial, in approximately are studies completed And sites as completed results am will and earlier the U.S. trial significant quarter previously XXXX read XXX expected the a XXXX. to enrolled to made clinical all at in at onboard expected of clinical the We designated than three are insomnia the XXX second been has also Europe are sites XXXX have XXXX. Top-line been expected. Enrollment U.S., Japan. and from from with Japan. patients the this pleased that of pleased line has also I report top with patients in progress out today, first in MDD trial In in the in trial trial as patient
XXXX the will the call updating turn Finally, I XXXX. with the to results enrolled enrollment activities designated clinical this trial to like study available at preparation forward XXX in look sites has be roluperidone. to in with now patients third commercial I are Rick expected been on as the U.S. in also near trial from second months the summarize over of Top-line a in Patient future. who important ongoing MDD to completed would the you trial. six quarter
